July 10, 2018, Autonomous University of Barcelona
A research team from the UAB led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy.
The therapy has been tested successfully in two different mouse models of obesity, induced either by diet or genetic mutations. In addition, the authors observed that when administered to healthy mice, the gene therapy promoted healthy ageing and prevented age-associated weight gain and insulin resistance.
After treatment with AAV-FGF21, mice lost weight and reduced fat accumulation and inflammation in adipose tissue; fat content (steatosis), inflammation and fibrosis of the liver were also reversed; this led to an increase in insulin sensitivity and in healthy ageing, without any adverse side effects.
The results have been reproduced after genetic manipulation of three different tissues (liver, adipose tissue or skeletal muscle) to produce the FGF21 protein. “This gives a great flexibility to the therapy, since it allows to select each time the most appropriate tissue, and in case some complication prevents manipulating any of the tissues, it can be applied to any of the others. When a tissue produces FGF21 protein and secretes it into the bloodstream, it will be distributed throughout the body,” says the director of the study Dr. Fatima Bosch.
The authors highlight the importance of these results, since “the prevalence of type 2 diabetes and obesity is growing at alarming rates around the world,” explains the UAB researcher and co-author of the study Claudia Jambrina. Obesity also increases the risk of mortality and represents an important risk factor for cardiovascular and immune diseases, hypertension, arthritis, neuro degenerative disorders and some types of cancer.
“This is the first time that long term reversion of obesity and insulin resistance have been achieved upon a one-time administration of a gene therapy, in an animal model that resembles obesity and type 2 diabetes in humans,” says the first author of the paper and UAB researcher Veronica Jimenez. “The results demonstrate that it is a safe and effective therapy.”
The results also reveal that the administration of the gene therapy protected against the risk of tumor formation in the liver in response to a hypercaloric diet for a prolonged period of time.
The native FGF21 protein has a short half-life when administered using conventional procedures. For this reason, the pharmaceutical industry has developed FGF21 analogues/mimetics and has already conducted clinical trials. FGF21 analogues/mimetics, however, require periodic administration to mediate clinical benefits, but may raise immunological issues associated to the administration of exogenous proteins. The gene therapy vectors used by Dr. Bosch’s team, however, induce the mice to produce for many years the same FGF21 hormone naturally produced by the body, after a single administration and without any adverse effects.
For Dr. Bosch the next step will be to “test this therapy in larger animals before moving to clinical trials with patients.” AAV-mediated gene therapy has been approved in Europe and the United States for the treatment of several diseases, due to its efficacy and safety profile. Similarly, there exists extensive clinical experience in applying AAV-mediated gene transfer to liver and skeletal muscle. Consequently, “the therapy described in this study constitutes the basis for the future clinical translation of FGF21 gene transfer to treat type 2 diabetes, obesity and related comorbidities,” Dr. Bosch concludes.
The results of the research are published today in EMBO Molecular Medicine.
Leave a Reply